Kezar Life Sciences, Inc. financial data

Symbol
KZR on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 703% % -30%
Debt-to-equity 21% % 8.5%
Return On Equity -63% % -4.7%
Return On Assets -52% % -3.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7,323,156 shares 0.37%
Common Stock, Shares, Outstanding 7,323,106 shares 0.37%
Entity Public Float $43,000,000 USD -75%
Common Stock, Value, Issued $7,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 7,323,106 shares 0.37%
Weighted Average Number of Shares Outstanding, Diluted 7,323,106 shares 0.37%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD -100%
Research and Development Expense $44,707,000 USD -38%
General and Administrative Expense $20,811,000 USD -12%
Operating Income (Loss) $65,506,000 USD 37%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $61,705,000 USD 36%
Earnings Per Share, Basic -8 USD/shares 55%
Earnings Per Share, Diluted -8 USD/shares 55%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $38,935,000 USD 12%
Marketable Securities, Current $51,281,000 USD -55%
Assets, Current $94,501,000 USD -40%
Property, Plant and Equipment, Net $2,175,000 USD -31%
Operating Lease, Right-of-Use Asset $1,050,000 USD -51%
Other Assets, Noncurrent $0 USD -100%
Assets $97,726,000 USD -40%
Accounts Payable, Current $911,000 USD -74%
Employee-related Liabilities, Current $2,115,000 USD -0.24%
Accrued Liabilities, Current $3,927,000 USD -59%
Liabilities, Current $13,376,000 USD -35%
Operating Lease, Liability, Noncurrent $0 USD -100%
Liabilities $14,750,000 USD -51%
Accumulated Other Comprehensive Income (Loss), Net of Tax $14,000 USD -87%
Retained Earnings (Accumulated Deficit) $475,986,000 USD -15%
Stockholders' Equity Attributable to Parent $82,976,000 USD -38%
Liabilities and Equity $97,726,000 USD -40%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $17,190,000 USD 25%
Net Cash Provided by (Used in) Financing Activities $1,304,000 USD
Net Cash Provided by (Used in) Investing Activities $13,742,000 USD -33%
Common Stock, Shares Authorized 250,000,000 shares 0%
Common Stock, Shares, Issued 7,323,106 shares 0.37%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $4,747,000 USD -93%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $38,935,000 USD 12%
Interest Paid, Excluding Capitalized Interest, Operating Activities $189,000 USD -44%
Deferred Tax Assets, Valuation Allowance $102,485,000 USD 24%
Deferred Tax Assets, Gross $103,144,000 USD 23%
Operating Lease, Liability $3,259,000 USD -51%
Depreciation $800,000 USD -33%
Payments to Acquire Property, Plant, and Equipment $8,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $61,798,000 USD 35%
Lessee, Operating Lease, Liability, to be Paid $3,437,000 USD -54%
Property, Plant and Equipment, Gross $9,322,000 USD -0.3%
Operating Lease, Liability, Current $3,259,000 USD -3.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,418,000 USD -40%
Lessee, Operating Lease, Liability, to be Paid, Year One $347,000 USD -91%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $178,000 USD -77%
Lessee, Operating Lease, Liability, to be Paid, Year Three $347,000 USD -92%
Deferred Tax Assets, Operating Loss Carryforwards $50,318,000 USD 17%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $5,007,000 USD 23%
Operating Lease, Payments $3,391,000 USD 17%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $251,000 USD -3.5%
Deferred Tax Assets, Net of Valuation Allowance $659,000 USD -48%
Share-based Payment Arrangement, Expense $10,643,000 USD -18%
Interest Expense $1,603,000 USD 6.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%